Abbott Laboratories $ABT Stock: Financial Solutions Advisory Group Inc. Trims Stake

Financial Solutions Advisory Group Inc. decreased its holdings in Abbott Laboratories (NYSE:ABT) by 46.3% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 12,667 shares of the healthcare product maker’s stock after selling 10,923 shares during the quarter. Financial Solutions Advisory Group Inc.’s holdings in Abbott Laboratories were worth $1,329,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Choreo LLC grew its position in Abbott Laboratories by 2.4% in the 3rd quarter. Choreo LLC now owns 102,570 shares of the healthcare product maker’s stock worth $10,137,000 after purchasing an additional 2,427 shares during the period. Interchange Capital Partners LLC raised its stake in Abbott Laboratories by 9.1% during the 3rd quarter. Interchange Capital Partners LLC now owns 14,682 shares of the healthcare product maker’s stock valued at $1,451,000 after buying an additional 1,227 shares during the last quarter. Livelsberger Financial Advisory purchased a new stake in Abbott Laboratories during the 3rd quarter valued at $326,000. Elwood & Goetz Wealth Advisory Group LLC lifted its holdings in shares of Abbott Laboratories by 3.1% during the 3rd quarter. Elwood & Goetz Wealth Advisory Group LLC now owns 3,216 shares of the healthcare product maker’s stock valued at $318,000 after buying an additional 97 shares during the period. Finally, Values Added Financial LLC lifted its holdings in shares of Abbott Laboratories by 5.8% during the 3rd quarter. Values Added Financial LLC now owns 3,912 shares of the healthcare product maker’s stock valued at $387,000 after buying an additional 216 shares during the period. Institutional investors own 75.18% of the company’s stock.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott initiated the pivotal CROWN-MV trial for its investigational Cephea™ Mitral Valve System. The minimally invasive device targets symptomatic mitral valve disease patients who are not eligible for surgery or existing transcatheter repair, creating a potential future growth opportunity in structural heart care. However, the device remains investigational and commercialization is still dependent on trial results and regulatory approval. Abbott initiates pivotal trial for Cephea device
• Positive Sentiment: The company launched a next-generation Oncodetect test designed to detect residual cancer disease. The release reinforces Abbott’s diagnostics pipeline and could support longer-term growth if the test gains clinical adoption. Abbott launches next-generation Oncodetect test
• Positive Sentiment: Abbott reportedly received approximately $23.9 million in net ETF buying, indicating some institutional demand for the shares, although ETF flows are not a measure of operating performance. Abbott sees net ETF buying
• Neutral Sentiment: Abbott’s planned separation of its roughly $8.5 billion Nutrition business could allow management to focus more closely on medical devices, diagnostics and pharmaceuticals, but it would also remove a sizable source of revenue diversification. The transaction remains subject to regulatory and internal approvals. Potential Abbott Nutrition spin-off
• Neutral Sentiment: Industry reports project growth in South and Central American point-of-care diagnostics and European medical foods, markets in which Abbott participates. These reports provide favorable demand context but do not represent new company-specific contracts or guidance.
• Negative Sentiment: Argus Research downgraded Abbott from Buy to Hold, potentially limiting near-term upside and signaling a less favorable risk-reward assessment. Argus downgrades Abbott to Hold

Abbott Laboratories Price Performance

Shares of Abbott Laboratories stock opened at $104.37 on Friday. The company has a market capitalization of $180.60 billion, a price-to-earnings ratio of 38.94, a PEG ratio of 1.80 and a beta of 0.59. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The stock’s 50-day simple moving average is $104.52 and its 200-day simple moving average is $102.15. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $132.02.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.42. Abbott Laboratories had a return on equity of 17.97% and a net margin of 9.75%. The firm had revenue of $13.01 billion during the quarter, compared to analysts’ expectations of $12.99 billion. During the same quarter last year, the business posted $1.30 earnings per share. The firm’s revenue was up 14.5% on a year-over-year basis. As a group, analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 94.03%.

Analysts Set New Price Targets

A number of research firms have recently issued reports on ABT. Argus downgraded Abbott Laboratories from a “buy” rating to a “hold” rating in a research note on Tuesday. Wells Fargo & Company upped their price objective on Abbott Laboratories from $112.00 to $119.00 and gave the company an “overweight” rating in a research report on Thursday, October 22nd. BTIG Research lowered their price objective on shares of Abbott Laboratories from $134.00 to $125.00 and set a “buy” rating on the stock in a research note on Thursday, October 22nd. Piper Sandler reissued an “overweight” rating and issued a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. Finally, TD Cowen cut their target price on shares of Abbott Laboratories from $135.00 to $118.00 and set a “buy” rating for the company in a research report on Thursday, October 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $118.32.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.